MONTEREY, Calif. — Women treated with Tyrvaya had consistent outcomes regardless of their menopause status, according to a study presented at the Women in Ophthalmology Summer Symposium.
Dagny Zhu, MD, and colleagues wrote in a poster presentation that post-menopausal women are at greater risk for dry eye disease (DED) due to hormonal dysregulation of ocular secretory glands.
“By activating the trigeminal parasympathetic pathway, OC-01 (varenicline solution nasal spray 0.03 mg, Oyster Point Pharma), a cholinergic agonist, is believed to increase endogenous tear production,”